Sunday, December 15, 2019 @ 12:00 am
Santersus AG (Switzerland), a privately held selective plasmapheresis start-up company, announces that the Company has strengthened its leadership team with the appointment of Mr. Simon Tallett to the newly created position of Development Director and Board Member.
Dr. Dmitry D. Genkin, co-founder of Santersus SA remarked, "Simon has established a solid reputation as a solutions-oriented, practical, and creative expert. The added firepower and focus that he brings to Santersus is expected to expedite the clinical and technical progress.”
Simon has extensive experience in the Healthcare and Life Science areas. After international academic studies in the fields of Microbiology/Virology and Pharmacology, Simon spent several years in various Clinical Pharmacist roles including Aseptics, Cardiology, Nephrology, Respiratory and Immunology. Simon has previous experience in clinical research in the Louise Cootes Centre at Guys and St Thomas Hospital, where he designed and led a research project looking at the effects of smoking on the efficacy of Hydroxychloroquine uptake in Lupus patients – Published in Arthritis & Rheumatism Abstract Supplement of American journal of Rheumatology (Volume 54, Number 9, September 2006) and presented in Washington D.C.
“I am honoured and extremely excited to be embarking on this journey with Santersus. This technology has the ability to change the course of both therapeutics and diagnostics in the years to come,” said Simon.
Mr. Tallett will also be assuming the role of Chief Development Officer.